Loading
HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Nivolumab, Pembrolizumab and Atezolizumab.
In plain words · HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
HLA-DRA (HLA class II histocompatibility antigen, DR alpha chain) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule.
No product in this corpus aims at HLA-DRA yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA HLA-DRA: RNA tissue enhanced (lung 931 nTPM, lymphoid tissue 1,197 nTPM); blood lineage group enriched (B-cells 420 nTPM, dendritic cells 231 nTPM, monocytes 409 nTPM); high antibody staining in 10 normal tissues; highest cancer staining lymphoma (4 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas HLA-DRA tissue; Open Targets ENSG00000204287 associations
First described 1982. Earliest sequence paper UniProt cites for the protein: Lee J.S. et al, Nature, 1982, "Sequence of an HLA-DR alpha-chain cDNA clone and intron-exon organization of the corresponding gene". Source.
Sources: HGNC HGNC:4947 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01903 (protein name, function text, keywords and locations (REST API)); CIViC gene HLA-DRA (1 evidence items, 0 assertions, 1 variants; diseases: Skin Melanoma (GraphQL API, CC0))
An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumour microenvironment, presents antigenic peptides that are primarily generated in tumour-resident APCs likely via phagocytosis of apoptotic tumour cells or macropinocytosis of secreted tumour proteins. Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance. Location: Cell membrane; Endoplasmic reticulum membrane; Early endosome membrane; Late endosome membrane (UniProt). Locus 6p21.32 (HGNC).
RNA: tissue enhanced (lung 931 nTPM, lymphoid tissue 1,197 nTPM), detected in many normal tissues. Blood: group enriched (B-cells 420 nTPM, dendritic cells 231 nTPM, monocytes 409 nTPM).
Medium: Adrenal gland, Bone marrow, Bronchus, Cerebral cortex, Fallopian tube, Gallbladder, Salivary gland, Seminal vesicle.
Medium only: pancreatic cancer, stomach cancer, thyroid cancer, urothelial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HLA-DRA" OR ABSTRACT:"HLA-DRA" OR TITLE:"major histocompatibility complex, class II, DR alpha" OR ABSTRACT:"major histocompatibility complex, class II, DR alpha" OR TITLE:"HLA class II histocompatibility antigen, DR alpha chain" OR ABSTRACT:"HLA class II histocompatibility antigen, DR alpha chain" OR TITLE:"HLA-DRA1" OR ABSTRACT:"HLA-DRA1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HLA-DRA, not a curated reading list.
Shares Checkpoint (two meanings), CIViC.
Shares Checkpoint (two meanings), CIViC.
Shares Checkpoint (two meanings), CIViC.
Shares Checkpoint (two meanings), CIViC, Melanoma.
Shares Checkpoint (two meanings), CIViC.
Shares Checkpoint (two meanings), CIViC.
Shares Checkpoint (two meanings), CIViC.